Nintedanib (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with Nintedanib.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with Nintedanib.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with Nintedanib.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Nintedanib.

Results found

Linked to

 

Label

Description

 

Gene

calcium/calmodulin dependent protein kinase kinase 1

Gene

RIO kinase 1

Gene

endoplasmic reticulum to nucleus signaling 1

Gene

protein kinase AMP-activated catalytic subunit alpha 1

Gene

ribosomal protein S6 kinase A6

Gene

mitogen-activated protein kinase 8

Gene

calcium/calmodulin dependent protein kinase IG

Gene

SH3 domain binding kinase family member 3

Gene

eukaryotic translation initiation factor 2 alpha kinase 4

Gene

oxidative stress responsive kinase 1

  • Gene

    calcium/calmodulin dependent protein kinase kinase 1



  • Gene

    endoplasmic reticulum to nucleus signaling 1


  • Gene

    protein kinase AMP-activated catalytic subunit alpha 1


  • Gene

    ribosomal protein S6 kinase A6


  • Gene

    mitogen-activated protein kinase 8


  • Gene

    calcium/calmodulin dependent protein kinase IG


  • Gene

    SH3 domain binding kinase family member 3


  • Gene

    eukaryotic translation initiation factor 2 alpha kinase 4


  • Gene

    oxidative stress responsive kinase 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.